GlassScriptPhysician profile
Amin Pasha
NPI 1861760050
$8,059.19
in general payments reported to CMS, 2019-2025
39 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $707 · 2021: $302 · 2022: $962 · 2023: $1,209 · 2024: $2,013 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,664 · Education: $87.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,664.40 |
| Education | $87.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $1,051.40 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Astrazeneca Pharmaceuticals LP | $1,008.93 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $768.11 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $694.53 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $584.82 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $536.23 | 2022-2025 | |
| Pulmonx Corporation | $382.15 | 2020-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Regeneron Healthcare Solutions, INC. | $350.23 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $290.05 | 2021-2025 | Prolastin-C Liquid |
| Electromed, INC. | $269.38 | 2019-2025 | Smartvest |
| Sunovion Pharmaceuticals INC. | $232.48 | 2019-2020 | |
| Inspire Medical Systems, INC. | $231.32 | 2023-2024 | Inspire |
| Janssen Pharmaceuticals, INC | $227.87 | 2019-2024 | Xarelto |
| Verona Pharma, INC. | $146.80 | 2025 | Ohtuvayre |
| Mallinckrodt Enterprises LLC | $126.18 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $111.37 | 2023-2024 | Yupelri |
| Bard Access Systems, INC. | $101.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.45 | 2020-2025 | |
| Viatris Specialty LLC | $87.17 | 2025 | Yupelri |
| Inari Medical, INC. | $86.82 | 2022 | |
| Jazz Pharmaceuticals INC. | $67.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Intuitive Surgical, INC. | $57.56 | 2025 | |
| Insmed, INC. | $55.96 | 2024-2025 | Arikayce, Brinsupri |
| Resmed Corp | $54.13 | 2022-2024 | |
| Teleflex LLC | $46.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.25 | 2024-2025 | Glassia |
| Lungpacer Medical USA INC | $40.36 | 2025 | Aeropace Neurostimulation Console |
| Circassia INC. | $37.84 | 2019 | |
| Merck Sharp & Dohme LLC | $31.30 | 2024-2025 | Winrevair |
| Mallinckrodt Hospital Products INC. | $28.74 | 2022 | |
| Csl Behring | $28.32 | 2019 | |
| Edwards Lifesciences Corporation | $22.77 | 2022 | |
| Harmony Biosciences LLC | $21.95 | 2021 | |
| Gilead Sciences, INC. | $20.95 | 2024 | Veklury |
| Ani Pharmaceuticals, INC. | $19.82 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $18.55 | 2023 | Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $12.88 | 2019 | |
| Veran Medical Technologies, INC. | $9.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amin Pasha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.